• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

恩度（重组人血管内皮抑制素）联合化疗对比单纯化疗治疗晚期非小细胞肺癌的系统评价和荟萃分析。

Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer.

机构信息

Department of Respiratory Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, 157 Xi-Wu Road, Xi'an, Shaanxi 710004, China.

出版信息

World J Surg Oncol. 2012 Aug 24;10:170. doi: 10.1186/1477-7819-10-170.

DOI:10.1186/1477-7819-10-170
PMID:22917490
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3517896/
Abstract

BACKGROUND

Many studies have investigated the efficacy of Endostar combined with platinum-based doublet chemotherapy (PBDC) versus PBDC alone for treating advanced non-small cell lung cancer (NSCLC). This study is a meta-analysis of available evidence.

METHODS

Fifteen studies reporting Endostar combined with PBDC versus PBDC alone for treating advanced NSCLC were reviewed. Pooled odds ratios and hazard ratio with 95% confidence intervals were calculated using either the fixed effects model or random effects model.

RESULTS

The overall response rate (ORR) and disease control rate (DCR) of Endostar combined with PBDC for treating NSCLC were significantly higher than those of PBDC alone, with 14.7% and 13.5% improvement, respectively (P < 0.00001). In addition, the time to progression (TTP) and quality of life (QOL) were improved after the treatment of Endostar combined with PBDC (P < 0.00001). The main adverse effects found in this review were hematological reactions, hepatic toxicity, and nausea/vomiting. Endostar combined with PBDC had a similar incidence of adverse reactions compared with PBDC alone (P < 0.05).

CONCLUSIONS

Endostar combined with PBDC was associated with higher RR, DCR, and TTP as well as superior QOL profiles compared with PBDC alone. Endostar combined with PBDC had a similar incidence of adverse reactions compared with PBDC alone.

摘要

背景

许多研究调查了恩度联合铂类双药化疗（PBDC）与单纯 PBDC 治疗晚期非小细胞肺癌（NSCLC）的疗效。本研究是对现有证据的荟萃分析。

方法

综述了 15 项报道恩度联合 PBDC 与单纯 PBDC 治疗晚期 NSCLC 的研究。使用固定效应模型或随机效应模型计算联合治疗组与单纯化疗组的优势比（OR）和风险比（HR）及 95%置信区间。

结果

恩度联合 PBDC 治疗 NSCLC 的总体缓解率（ORR）和疾病控制率（DCR）显著高于单纯 PBDC 组，分别提高了 14.7%和 13.5%（P<0.00001）。此外，恩度联合 PBDC 治疗后，无进展生存期（TTP）和生活质量（QOL）得到改善（P<0.00001）。本综述中发现的主要不良反应是血液学反应、肝毒性和恶心/呕吐。与单纯 PBDC 相比，恩度联合 PBDC 组的不良反应发生率相似（P<0.05）。

结论

与单纯 PBDC 相比，恩度联合 PBDC 可提高 RR、DCR 和 TTP，改善 QOL。与单纯 PBDC 相比，恩度联合 PBDC 的不良反应发生率相似。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6015/3517896/d2ea239c34b3/1477-7819-10-170-8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6015/3517896/2f809abaac1e/1477-7819-10-170-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6015/3517896/1f789599241e/1477-7819-10-170-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6015/3517896/da1ef703debe/1477-7819-10-170-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6015/3517896/efcec1baf41d/1477-7819-10-170-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6015/3517896/a2cf30283b0b/1477-7819-10-170-5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6015/3517896/51532cff8a73/1477-7819-10-170-6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6015/3517896/a00ca33fad51/1477-7819-10-170-7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6015/3517896/d2ea239c34b3/1477-7819-10-170-8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6015/3517896/2f809abaac1e/1477-7819-10-170-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6015/3517896/1f789599241e/1477-7819-10-170-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6015/3517896/da1ef703debe/1477-7819-10-170-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6015/3517896/efcec1baf41d/1477-7819-10-170-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6015/3517896/a2cf30283b0b/1477-7819-10-170-5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6015/3517896/51532cff8a73/1477-7819-10-170-6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6015/3517896/a00ca33fad51/1477-7819-10-170-7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6015/3517896/d2ea239c34b3/1477-7819-10-170-8.jpg

相似文献

1
Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer.恩度（重组人血管内皮抑制素）联合化疗对比单纯化疗治疗晚期非小细胞肺癌的系统评价和荟萃分析。
World J Surg Oncol. 2012 Aug 24;10:170. doi: 10.1186/1477-7819-10-170.
2
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
3
Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis.双联与单药细胞毒药物一线治疗老年晚期非小细胞肺癌的系统评价和荟萃分析。
Lung. 2012 Oct;190(5):477-85. doi: 10.1007/s00408-012-9399-3. Epub 2012 Jun 19.
4
Chemotherapy for advanced non-small cell lung cancer in the elderly population.老年晚期非小细胞肺癌的化疗
Sao Paulo Med J. 2016 Sep-Oct;134(5):465-466. doi: 10.1590/1516-3180.20161345T1.
5
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.晚期表皮生长因子受体（EGFR）突变阳性非鳞状非小细胞肺癌的一线治疗
Cochrane Database Syst Rev. 2016 May 25(5):CD010383. doi: 10.1002/14651858.CD010383.pub2.
6
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
7
Platinum-containing regimens for metastatic breast cancer.转移性乳腺癌的含铂方案。
Cochrane Database Syst Rev. 2017 Jun 23;6(6):CD003374. doi: 10.1002/14651858.CD003374.pub4.
8
Aidi injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer: A meta-analysis of 42 RCTs following the PRISMA guidelines.艾迪注射液联合铂类化疗方案治疗ⅢB/Ⅳ期非小细胞肺癌的 Meta 分析：遵循 PRISMA 指南的 42 项 RCT 研究的汇总分析。
J Ethnopharmacol. 2018 Jul 15;221:137-150. doi: 10.1016/j.jep.2018.04.013. Epub 2018 Apr 12.
9
Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials.以顺铂和卡铂为基础的双联化疗方案与非铂类双联化疗方案作为转移性非小细胞肺癌一线治疗的疗效和副作用：一项随机对照试验的系统评价
Lung Cancer. 2008 Jan;59(1):1-11. doi: 10.1016/j.lungcan.2007.07.012. Epub 2007 Aug 27.
10
Gefitinib for advanced non-small cell lung cancer.吉非替尼用于治疗晚期非小细胞肺癌。
Cochrane Database Syst Rev. 2018 Jan 16;1(1):CD006847. doi: 10.1002/14651858.CD006847.pub2.

引用本文的文献

1
Efficacy analysis of endostar combined with chemoradiotherapy and immune checkpoint inhibitors in locally advanced non-small cell lung cancer.恩度联合放化疗及免疫检查点抑制剂治疗局部晚期非小细胞肺癌的疗效分析
Discov Oncol. 2025 Jul 7;16(1):1272. doi: 10.1007/s12672-025-03044-7.
2
Beyond biomarkers: Exploring the diverse potential of a novel phosphoprotein in lung cancer management.超越生物标志物：探索新型磷酸化蛋白在肺癌管理中的多样潜能。
J Cell Mol Med. 2024 Sep;28(18):e70077. doi: 10.1111/jcmm.70077.
3
Extracellular vesicle-bound VEGF in oral squamous cell carcinoma and its role in resistance to Bevacizumab Therapy.

本文引用的文献

1
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer.一项多中心、随机、双盲、安慰剂对照研究，旨在评估紫杉醇-卡铂单独或联合恩度治疗晚期非小细胞肺癌的疗效。
J Thorac Oncol. 2011 Jun;6(6):1104-9. doi: 10.1097/JTO.0b013e3182166b6b.
2
A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer.一项重组人血管内皮抑制素联合吉西他滨/顺铂与吉西他滨/顺铂单药一线治疗晚期非小细胞肺癌的随机 II 期研究。
Invest New Drugs. 2012 Jun;30(3):1144-9. doi: 10.1007/s10637-011-9631-7. Epub 2011 Jan 12.
3
口腔鳞状细胞癌中细胞外囊泡结合的血管内皮生长因子及其在贝伐单抗治疗耐药中的作用
Cancer Cell Int. 2024 Aug 23;24(1):296. doi: 10.1186/s12935-024-03476-1.
4
Efficacy and outcome analysis: Combination of Endostar and chemotherapy as a neoadjuvant treatment of stage IIIA/IIIB squamous cell lung cancer.疗效与结果分析：恩度与化疗联合作为IIIA/IIIB期肺鳞状细胞癌的新辅助治疗
Oncol Lett. 2023 Nov 16;27(1):23. doi: 10.3892/ol.2023.14156. eCollection 2024 Jan.
5
A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC.一项关于恩度联合化疗治疗 EGFR-TKI 耐药 NSCLC 的疗效和安全性的回顾性研究。
BMC Pulm Med. 2023 Nov 11;23(1):437. doi: 10.1186/s12890-023-02705-z.
6
A real-world study of recombinant human endostatin combined with PD-1/PD-L1 blockade and chemotherapy for patients with advanced non-small cell lung cancer negative for actionable molecular biomarkers.一项针对晚期非小细胞肺癌患者的真实世界研究，这些患者的可操作分子生物标志物为阴性，研究使用了重组人血管内皮抑制素联合 PD-1/PD-L1 阻断和化疗。
Medicine (Baltimore). 2023 Oct 13;102(41):e35243. doi: 10.1097/MD.0000000000035243.
7
Recombinant Endostatin as a Potential Radiosensitizer in the Treatment of Non-Small Cell Lung Cancer.重组内皮抑素作为非小细胞肺癌治疗中一种潜在的放射增敏剂。
Pharmaceuticals (Basel). 2023 Jan 31;16(2):219. doi: 10.3390/ph16020219.
8
Extended use of rh-endostatin improves prognosis in patients with advanced non-small cell lung cancer: an analysis of retrospective study.重组人血管内皮抑制素的延长使用可改善晚期非小细胞肺癌患者的预后：一项回顾性研究分析
J Thorac Dis. 2022 Nov;14(11):4416-4426. doi: 10.21037/jtd-22-1292.
9
Primary tumor-derived systemic nANGPTL4 inhibits metastasis.原发肿瘤衍生的系统性 nANGPTL4 抑制转移。
J Exp Med. 2023 Jan 2;220(1). doi: 10.1084/jem.20202595. Epub 2022 Oct 21.
10
Anti-Angiogenic Therapy in Rearranged Non-Small Cell Lung Cancer (NSCLC).抗血管生成治疗在非小细胞肺癌（NSCLC）中的应用。
Int J Mol Sci. 2022 Aug 9;23(16):8863. doi: 10.3390/ijms23168863.
Meta-analysis of thyroidectomy with ultrasonic dissector versus conventional clamp and tie.超声刀甲状腺切除术与传统钳夹结扎术的荟萃分析
World J Surg Oncol. 2010 Dec 23;8:112. doi: 10.1186/1477-7819-8-112.
4
[Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients].[重组人血管内皮抑素（YH-16）治疗晚期非小细胞肺癌患者的随机、多中心、双盲III期临床试验结果]
Zhongguo Fei Ai Za Zhi. 2005 Aug 20;8(4):283-90. doi: 10.3779/j.issn.1009-3419.2005.04.07.
5
Safety and resource utilization by non-small cell lung cancer histology: results from the randomized phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaïve patients with advanced non-small cell lung cancer.非小细胞肺癌组织学的安全性和资源利用：在未经化疗的晚期非小细胞肺癌患者中，培美曲塞联合顺铂与吉西他滨联合顺铂的随机 III 期研究结果。
J Thorac Oncol. 2010 Oct;5(10):1602-8. doi: 10.1097/JTO.0b013e3181eaf30f.
6
[Clinical observation on the target therapy of rh-endostin, combined with chemotherapy in advanced non-small cell lung cancer.].重组人血管内皮抑素联合化疗靶向治疗晚期非小细胞肺癌的临床观察
Zhongguo Fei Ai Za Zhi. 2009 Jul 20;12(7):780-4. doi: 10.3779/j.issn.1009-3419.2009.07.007.
7
Traditional Chinese Medicine for treatment of fibromyalgia: a systematic review of randomized controlled trials.中医治疗纤维肌痛症的疗效：一项随机对照试验的系统评价。
J Altern Complement Med. 2010 Apr;16(4):397-409. doi: 10.1089/acm.2009.0599.
8
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.顺铂联合吉西他滨加安慰剂或贝伐单抗作为非鳞状非小细胞肺癌一线治疗的III期试验：AVAil研究
J Clin Oncol. 2009 Mar 10;27(8):1227-34. doi: 10.1200/JCO.2007.14.5466. Epub 2009 Feb 2.
9
Process in the mechanisms of endostatin combined with radiotherapy.内皮抑素联合放疗机制中的过程。
Cancer Lett. 2009 Sep 8;282(1):9-13. doi: 10.1016/j.canlet.2008.12.008. Epub 2009 Jan 10.
10
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.贝伐单抗联合伊立替康、5-氟尿嘧啶和亚叶酸钙或5-氟尿嘧啶和亚叶酸钙用于转移性结直肠癌对健康相关生活质量的影响。
Oncologist. 2008 Sep;13(9):1021-9. doi: 10.1634/theoncologist.2008-0003. Epub 2008 Sep 5.